In lat­est set­back for stem cell sec­tor, Celyad fails PhI­II— and the biotech claims a vic­to­ry

At first glance, the idea that stem cells can be used to strength­en a dam­aged heart has a po­tent at­trac­tion. It sounds sen­si­ble enough in the panoply of re­gen­er­a­tive med­i­cine. But Celyad’s pro­gram to prove that it has the right ap­proach with Cure-C just failed in Phase III, of­fer­ing a new set­back to a trou­bled field and a body blow to the biotech com­pa­ny.

For Celyad’s ($CYAD) part, the fact that the Phase III failed was dis­pensed with quick­ly so the com­pa­ny could im­me­di­ate­ly move on to its an­a­lyt­i­cal break­down, point­ing to a sig­nif­i­cant sub­pop­u­la­tion of pa­tients the com­pa­ny in­sists were helped by C-Cure. That analy­sis is giv­ing them grounds to ap­proach the EMA on fil­ing the drug while flag­ging their ea­ger­ness to do a deal on the project, look­ing for an­oth­er com­pa­ny to fund de­vel­op­ment and back a com­mer­cial­iza­tion move.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER